Welcome to our dedicated page for AINOS news (Ticker: AIMDW), a resource for investors and traders seeking the latest updates and insights on AINOS stock.
Ainos Inc (AIMDW) is a biotechnology innovator merging AI-driven diagnostics with novel interferon therapeutics. This page provides centralized access to official announcements, clinical trial updates, and strategic developments across its human and animal health divisions.
Investors and industry stakeholders will find timely updates on VELDONA therapeutic progress, AI Nose technology deployments, and regulatory milestones. Content spans earnings reports, partnership announcements, product launch details, and peer-reviewed research findings.
Key focus areas include advancements in low-dose oral interferon formulations for rare disease treatment and AI-powered VOC detection systems for telehealth applications. All materials adhere to factual reporting standards, ensuring reliable tracking of the company’s dual therapeutic and diagnostic pipelines.
Bookmark this page for streamlined monitoring of Ainos’ innovations in AI-driven healthcare solutions and biotechnology commercialization efforts.
Ainos (NASDAQ:AIMD) has secured a Taiwan invention patent for VELDONA®, its breakthrough formulation for coronavirus treatment and prevention. The company has also filed for global patent protection under the Patent Cooperation Treaty (PCT). VELDONA® utilizes an advanced oral rapid-dissolving tablet technology that enhances immune system function and reduces the risk of coronavirus infections.
Key highlights:
- VELDONA® shows potential in activating the immune system against various coronavirus variants and preventing new infections
- The technology may extend to other viral diseases, including Hepatitis B, HIV, and various animal viruses
- Ainos believes VELDONA® could become a competitive, comprehensive antiviral therapy due to its high efficacy, safety, and low side effects
Ainos (NASDAQ: AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and VELDONA low-dose interferon therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person at the Lotte New York Palace Hotel and virtually on September 9-10, 2024.
Key highlights:
- Ainos will conduct one-on-one meetings during the conference
- Mr. Jack Lu, Director of Corporate Development, will deliver a live presentation on September 10, 2024, at 4 p.m.
- The company invites shareholders and interested parties to learn about their journey towards becoming 'AI's nose' capable of digitizing smell
- Interested attendees can register for the conference through the HCW Events website
Ainos, Inc. (NASDAQ:AIMD) is making significant strides in AI-powered smell digitization technology. CEO Chun-Hsien Tsai highlighted key achievements and upcoming milestones in a shareholder letter:
1. AI Nose Technology: Ainos is developing AI-powered digital nose sensors for healthcare and smart factories.
2. Healthcare Applications: The next-gen Ainos Flora, targeting women's health and STI testing, is set for clinical trials in Q4 2024.
3. Elderly Care: Collaborating with Nisshinbo Micro Devices and Taiwan Inabata Sangyo, Ainos aims for pilot production in Q4 2024.
4. Smart Factories: AI Nose achieved 79% accuracy in identifying VOCs in semiconductor factories, with pilot production ready in Q4 2024.
5. IP Portfolio: Ainos secured exclusive licenses for 10 multi-region patents related to gas sensors and medical device technologies.
Ainos (NASDAQ: AIMD) has unveiled a breakthrough in its AI Nose technology, achieving 79% accuracy in identifying 761 samples across 22 volatile organic compounds (VOCs) in Japanese semiconductor manufacturing factories. This advancement significantly enhances smart manufacturing factory automation and safety. The AI Nose can detect manufacturing process contamination, ensure health and safety, prevent fires, and optimize gas sensing with real-time feedback.
Ainos plans to integrate AI Nose into smart factory robotics systems, equipping robots with a human-like sense of smell to improve collaboration with workers and enhance safety. This development expands AI Nose's applications beyond medical uses into the industrial sector, positioning Ainos as a leader in VOC sensing technology.
Ainos Inc. (NASDAQ:AIMD) announced its participation in a fireside chat with Water Tower Research on August 22, 2024, at 10:00 a.m. ET. Jack Lu, Director of Corporate Development, will present an overview of Ainos' business model, strategic priorities, and AI Nose technology platform. The discussion will cover lead pipeline products, including the low-dose IFN-α therapeutic VELDONA, and its potential in human and animal health.
The fireside chat will also address Ainos' recent earnings and financial position. This listen-only event is open for registration, and a replay will be available on the company's investor relations website. Ainos is a diversified healthcare company focusing on AI-powered point-of-care testing (POCT) and VELDONA therapeutics.
Ainos, Inc. (NASDAQ:AIMD) has secured exclusive licenses for 10 invention patents and patent applications from Taiwan Carbon Nano Technology (TCNT), its affiliate and product co-developer. The licenses, valued at approximately $5.4 million, cover gas sensors and medical devices across multiple regions including the U.S., Germany, China, Japan, and Taiwan. The all-stock licensing structure aligns TCNT's interests with Ainos shareholders while preserving cash for growth.
This strategic move is expected to strengthen Ainos' AI Nose and Point-Of-Care Testing (POCT) technologies. The company is advancing its AI Nose and POCT pipeline, including the leading volatile organic compounds (VOC) POCT candidate, Ainos Flora. Ainos is also developing a VOC sensing platform with Japanese partners and progressing on the Next-Gen Ainos Flora, which implements NVIDIA CUDA technology.
Ainos (NASDAQ:AIMD) reported its Q2 2024 financial results, highlighting progress in its VELDONA® animal health initiatives. The company enrolled its first subject for an FCGS clinical study, marking a shift towards drug development in animal health. Ainos raised $9 million through convertible note financing, ensuring a 12+ month financial runway. Q2 2024 saw nominal revenues and a net loss of $3,195,022. R&D expenses increased to $1,978,756, while SG&A expenses rose to $1,044,880. The company's cash position improved to $8,014,098 as of June 30, 2024. Ainos is advancing its AI Nose technology and VELDONA® human drug candidates, aiming to maximize long-term shareholder value.
Ainos announces significant progress in the clinical trials of its AI Nose-powered Ainos Flora device, designed for rapid, non-invasive detection of bacterial, fungal, and common sexually transmitted infections in women. The trials, conducted at four major medical centers in Taiwan, successfully tested 75 cases, validating the AI algorithm's accuracy through real-world data incorporation and comprehensive data standardization.
Building on current trial success, Ainos aims to develop a next-gen Ainos Flora with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trials. The new device will feature improvements for at-home testing, addressing growing demand for decentralized healthcare solutions. The STI testing market is projected to reach $256 billion by 2028, with POCT accounting for 31%.
Ainos' ongoing innovation in AI and medical technology is supported by over 50 patents. The Ainos Flora device won the 2021 iF's Medicine/Health Design Award, highlighting its effectiveness and user-friendly design for home healthcare.
Ainos, a diversified healthcare company, released its Q1 2024 financial results. The company reported a strategic shift from COVID-19 rapid test kits, affecting near-term revenues, with Q1 revenue dropping to $20,729 from $49,164 in Q1 2023. Cost of revenues also decreased to $26,754 from $100,848. Despite this, gross profit improved, narrowing the loss to $6,025 from a $51,684 loss a year ago. Total operating expenses rose to $3.11M, attributed to higher clinical trial fees and research costs. Net loss widened to $3.31M from $2.52M. Recent financing efforts secured $9M in growth capital and an additional $1.75M in January 2024, bolstering Ainos' position for continued growth. CEO Chun-Hsien Tsai emphasized the focus on AI Nose and VELDONA technologies, exploring new markets, and advancing clinical studies.
Ainos, Inc. raises $9 million in growth capital through a convertible note with an existing shareholder. The capital will be used to scale up the company's VELDONA and AI Nose growth initiatives. Ainos aims to advance its AI Nose platform and VELDONA investigational new drugs, propelling the company forward in advancing clinical studies and pursuing out-licensing opportunities.
FAQ
What is the current stock price of AINOS (AIMDW)?
